Clinical Study

Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism

Table 2

Assessment of response to treatment with sirolimus and outcome.

Patient no.Age of starting sirolimusDose of sirolimus of starting (mg/m2)Final dose of sirolimus (mg/m2)Response to treatment with sirolimusDuration of treatmentSide effectsOutcomes and follow-up

18 weeks0.50.2 and, then, discontinuedDiscontinued dextrose therapy after 10 days3 monthsNoneContinue sirolimus therapy for 3 months, no hypoglycemic episodes for one year after tapering sirolimus. Eurodevelopmental growth compatible with the age

214 weeks0.51.5Discontinued dextrose therapy after 15 days and octreotide after 20 daysMore than one year until the presentMild transient elevation of liver aminotransferase levelsReduced hypoglycemic episodes for 6 months after receiving sirolimus, continued plus diazoxide, and developmental delay

34 weeks0.5Discontinued dextrose therapy after 17 days and diazoxide/octreotide after 20–24 daysMore than one year (continued until now)NoneReduced hypoglycemic episodes for 6 months after receiving sirolimus. In 14 months of age, neurodevelopmental growth compatible with the age

46 weeks0.51–1.5Recurrent attacks of hypoglycemia and seizure, discontinued after 6 months6 monthsNoneRecurrent hypoglycemia ended up in pancreatectomy after 6 months of receiving sirolimus, after pancreatectomy (focal hyperplasia in histologic findings) diazoxide therapy with minimal dose continued

53 weeks0.50.5–0.7Discontinued dextrose therapy after 25 days, continued diazoxide 15 mg/kg/d and octreotide 10 mcg/kg/d8 months (discontinued follow-up after 8 months)NoneReduced hypoglycemic episodes for 6 months after receiving sirolimus (no seizure or poor feeding) adequate developmental growth

65 years0.50.5Continued diazoxide (10–15 mg/kg/d)More than one year, continued until nowNoneAfter surgery, the hypoglycemia episode was controlled by sirolimus plus diazoxide. No attacks of seizures, reduced hypoglycemia less than 1 time in the week